Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas.

abstract：:Forty-three patients with persistent and polyclonal B-cell lymphocytosis (PPBL) were studied. The PPBL diagnosis was based on the presence of a polyclonal lymphocytosis and the detection of binucleated lymphoid cells on peripheral blood examination. In order to define the cytogenetic profile in these patients, convent...

journal_title：Leukemia & lymphoma

authors： Mossafa H,Tapia S,Flandrin G,Troussard X,Groupe Français d'Hématologie Cellulaire (GFHC).

更新日期：2004-07-01 00:00:00

abstract：:Infection, relapse, and GVHD can complicate allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although the effect of poor immune recovery on infection risk is well-established, there are limited data on the effect of immune reconstitution on relapse and survival, especially following T-cell depletion (TC...

journal_title：Leukemia & lymphoma

authors： Goldberg JD,Zheng J,Ratan R,Small TN,Lai KC,Boulad F,Castro-Malaspina H,Giralt SA,Jakubowski AA,Kernan NA,O'Reilly RJ,Papadopoulos EB,Young JW,van den Brink MR,Heller G,Perales MA

更新日期：2017-08-01 00:00:00

abstract：:Recent data suggest that myeloid neoplasms are organized hierarchically in terms of self-renewal and maturation of early progenitor cells, similar to normal myelopoiesis. In acute myeloid leukemia (AML), the NOD/SCID mouse-repopulating leukemic stem cells usually co-express CD123 with CD34, but lack CD38. So far, howe...

journal_title：Leukemia & lymphoma

authors： Florian S,Sonneck K,Hauswirth AW,Krauth MT,Schernthaner GH,Sperr WR,Valent P

更新日期：2006-02-01 00:00:00

abstract：:Myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) are three classic BCR ABL fusion gene-negative chronic myeloproliferative neoplasms (MPNs). Though rare, it is important to understand the burden of illness of these disorders for public health planning, healthcare insurers and pharmaceutica...

journal_title：Leukemia & lymphoma

authors： Mehta J,Wang H,Iqbal SU,Mesa R

更新日期：2014-03-01 00:00:00

abstract：:B chronic lymphocytic leukemia (B-CLL) and hairy cell leukemia (HCL) cells are refractory to many of the signals which activate normal B cells but are stimulated to proliferate by tumor necrosis factor (TNF). Cell signalling by TNF is mediated in part by the induction of the transcription factor families AP-1 and NF-k...

journal_title：Leukemia & lymphoma

authors： Jabbar SA,Hoffbrand AV,Wickremasinghe RG

更新日期：1995-06-01 00:00:00

abstract：:Leukemia is a result of accumulating genetic alterations. The collaboration of mutations that offer survival and proliferative signals, together with mutations that result in lack of differentiation, is thought to cause a leukemic phenotype. The cyclic-AMP Response Element Binding Protein (CREB) is a transcription fac...

journal_title：Leukemia & lymphoma

authors： Shankar DB,Sakamoto KM

更新日期：2004-02-01 00:00:00

abstract：:B-cell chronic lymphocytic leukemia (CLL) is a clonal B cell malignancy of morphologically mature, functionally immature B cells. B-cell CLL cells are known to be resistant to killing by anticancer and other agents. This resistance is associated with alterations in apoptosis and cell cycle regulated genes. In our earl...

journal_title：Leukemia & lymphoma

authors： Wang P,Pavletic ZS,Joshi SS

更新日期：2002-09-01 00:00:00

abstract：:The prednisone, etoposide, procarbazine and cyclophosphamide (PEP-C) oral combination chemotherapy regimen (prednisone 20 mg, cyclophosphamide 50 mg, etoposide 50 mg, and procarbazine 50 mg with an oral anti-emetic) was employed at our center to treat 22 patients with heavily pretreated, recurrent mantle cell lymphoma...

journal_title：Leukemia & lymphoma

authors： Coleman M,Martin P,Ruan J,Furman R,Niesvizky R,Elstrom R,George P,Leonard J,Kaufmann T

更新日期：2008-03-01 00:00:00

abstract：:An increasing incidence of Pneumocystis jiroveci pneumonia (PCP) in patients with B-cell non-Hodgkin lymphoma (B-NHL) receiving rituximab treatment has been reported. We reviewed patients with B-NHL who underwent chemotherapy from 2004 to 2008 at our institution to identify risk factors for PCP development during and ...

journal_title：Leukemia & lymphoma

authors： Hashimoto K,Kobayashi Y,Asakura Y,Mori M,Azuma T,Maruyama D,Kim SW,Watanabe T,Tobinai K

更新日期：2010-10-01 00:00:00

abstract：:Hydroxyurea (HU) has traditionally been the first-line treatment for patients with polycythemia vera (PV) or essential thrombocythemia (ET) at high risk for vascular complications. However, approximately 20-25% of patients develop resistance or intolerance to HU and must be treated with second-line therapies. Resistan...

journal_title：Leukemia & lymphoma

authors： Sever M,Newberry KJ,Verstovsek S

更新日期：2014-12-01 00:00:00

abstract：:Interleukin-6 (IL-6) is the major growth factor for the malignant plasma cell clone in patients with multiple myeloma (MM). Although interferon-alpha (IFN-alpha) has been widely used as maintenance therapy in MM, controversy exists as to its clinical utility. This review summarizes data showing that cell growth arrest...

journal_title：Leukemia & lymphoma

authors： Hawley RG,Berger LC

更新日期：1998-05-01 00:00:00

abstract：:Tsg101 is a mouse tumor suppressor gene whose homozygous deletion produces transformation of NIH3T3 cells and leads to metastases in nude mice. The human homologue of the gene, TSG101, is localized in chromosome 11p15.1-p15.2. Reduced TSG101 expression may cause the defect of the cell cycle checkpoint that leads to ge...

journal_title：Leukemia & lymphoma

authors： Lin SF,Lin PM,Liu TC,Chang JG,Sue YC,Chen TP

更新日期：2000-02-01 00:00:00

abstract：:Recent advances in the treatment of patients with non-Hodgkin lymphoma have driven a paradigm shift from standard chemotherapy to an ever-expanding choice of targeted agents and combinations. As an orally bioavailable immunomodulator with antineoplastic, immunologic, and antiproliferative activity in B-cell lymphoma, ...

journal_title：Leukemia & lymphoma

authors： Galanina N,Petrich A,Nabhan C

更新日期：2016-07-01 00:00:00

abstract：:The standard CHOP regimen may cure 30-40% of patients with advanced aggressive non-Hodgkin's lymphoma (ANHL). Mitoxantrone is an anthracenedione, which is active in NHL and its toxicity profile may be more favorable than doxorubicin with respect to alopecia, mucositis and cardiotoxicity. This study was designed to com...

journal_title：Leukemia & lymphoma

authors： Pangalis GA,Vassilakopoulos TP,Michalis E,Roussou P,Vrakidou E,Repousis P,Angelopoulou MK,Siakantaris MP,Korantzis J,Symeonidis A,Grigorakis V,Stefanoudakis E,Stamatellou M,Bourantas KL,Kalmantis T,Christopoulos G,Kokkini

更新日期：2003-04-01 00:00:00

abstract：:The addition of arsenic trioxide (ATO) to frontline therapy of acute promyelocytic leukemia (APL) has been shown to result in significant improvements in disease-free survival (DFS). FLT3 mutations are frequently observed in APL, but its prognostic significance remains unclear. We analyzed 245 newly diagnosed adult pa...

journal_title：Leukemia & lymphoma

authors： Poiré X,Moser BK,Gallagher RE,Laumann K,Bloomfield CD,Powell BL,Koval G,Gulati K,Holowka N,Larson RA,Tallman MS,Appelbaum FR,Sher D,Willman C,Paietta E,Stock W

更新日期：2014-07-01 00:00:00

abstract：:Central nervous system (CNS) relapse is a challenging complication in patients with diffuse large B-cell lymphoma (DLBCL). Thus, identification of the high-risk population, in whom prophylactic treatment may play a significant role, is critical. We calculated the incidence of CNS relapse and evaluated the risk factors...

journal_title：Leukemia & lymphoma

authors： Chihara D,Oki Y,Matsuo K,Onoda H,Taji H,Yamamoto K,Morishima Y

更新日期：2011-12-01 00:00:00

abstract：:Leukemic lymphoblasts in B-lineage acute lymphoblastic leukemia (ALL) express morphologic, phenotypic and genotypic features which resemble those of B lymphocyte progenitors in normal bone marrow. Normal immature B cells and cells from most cases of B-lineage ALL rapidly die in vitro unless they are supported by bone ...

journal_title：Leukemia & lymphoma

authors： Campana D,Coustan-Smith E,Kumagai MA,Manabe A

更新日期：1994-05-01 00:00:00

abstract：:Autologous stem cell transplantation (ASCT), intensifying anti-leukemic effects without significant treatment-related mortality (TRM), is particularly appealing in AML with favorable genetic/molecular profile. This study retrospectively evaluated the outcomes of post-remission treatment in consecutive favorable-risk A...

journal_title：Leukemia & lymphoma

authors： Beyar-Katz O,Lavi N,Ringelstein-Harlev S,Henig I,Yehudai-Ofir D,Haddad N,Fineman R,Ofran Y,Nov Y,Sahar D,Moustafa-Hawash N,Rowe JM,Zuckerman T

更新日期：2019-10-01 00:00:00

abstract：:We report a 50-year-old patient with idiopathic hypereosinophilic syndrome with trisomy 8 who experienced a complete and durable hematological and cytogenetic remission with low-dose imatinib therapy. He also had a significant reversal of cardiac dysfunction with a reduction in cardiac hypertrophy, resolution of peric...

journal_title：Leukemia & lymphoma

authors： Onitilo AA,Kio EA,Singh AK,Lazarchick J

更新日期：2005-11-01 00:00:00

abstract：:The myelodysplastic syndromes (MDS) are a heterogeneous group of disorders of hematopoiesis entailing hyperproliferative and ineffective hematopoiesis resulting in refractory cytopenia(s), and increased risk of transformation into acute myeloblastic leukemia (AML). The widely used classification defined by the French-...

journal_title：Leukemia & lymphoma

authors： Sawada K

更新日期：1994-06-01 00:00:00

abstract：:Ponatinib is a pan-tyrosine kinase inhibitor (TKI) with efficacy in multirefractory CML patients who have failed other TKIs. Despite excellent response rates, resistance or intolerance may develop. We conducted a retrospective review of the outcome of patients with chronic (CP) and accelerated (AP) phase CML refractor...

journal_title：Leukemia & lymphoma

authors： Boddu P,Shah AR,Borthakur G,Verstovsek S,Garcia-Manero G,Daver N,Kadia T,Ravandi F,Jain N,Alhuraiji A,Burger J,Kornblau S,Pierce S,Dellasala S,Jabbour E,Kantarjian H,Cortes J

更新日期：2018-06-01 00:00:00

abstract：:Monoclonal IgM-related neuropathies constitute a heterogeneous group of disorders, which are generally poorly responsive to treatment. Rituximab, a chimeric monoclonal antibody against the CD20 molecule, has been used with success in patients with neuropathy and monoclonal IgM with anti-MAG or anti-GM1 ganglioside act...

journal_title：Leukemia & lymphoma

authors： Kilidireas C,Anagnostopoulos A,Karandreas N,Mouselimi L,Dimopoulos MA

更新日期：2006-05-01 00:00:00

abstract：:The mammalian target of rapamycin (mTOR) pathway is a major therapeutic target in the treatment of hematological malignancies, as it controls cellular events of high importance for regulation of mRNA translation and protein production. Rapalogs, or first-generation mTOR inhibitors, have produced only modest clinical b...

journal_title：Leukemia & lymphoma

authors： Mohindra NA,Platanias LC

更新日期：2015-01-01 00:00:00

abstract：:Over the last decade, the Janus kinase1/2 (JAK1/2) inhibitor ruxolitinib has emerged as a cornerstone of myelofibrosis (MF) management. Ruxolitinib improves splenomegaly and symptoms regardless of driver mutation status, and confers a survival advantage in patients with intermediate-2/high risk MF. However, cytopenias...

journal_title：Leukemia & lymphoma

authors： Bose P,Verstovsek S

更新日期：2020-08-01 00:00:00

abstract：:Current chemoimmunotherapy is unable to cure up to 40% of patients diagnosed with diffuse large B-cell lymphoma (DLBCL). Targeting the mechanisms by which DLBCL evades apoptosis is crucial to overcoming treatment failure in this heterogeneous disease as both current and novel treatments depend on the apoptosis of mali...

journal_title：Leukemia & lymphoma

authors： Gifford G,Stevenson W,Best G

更新日期：2020-12-01 00:00:00

abstract：:Ninety-nine patients with "standard risk" Stage IA-IIA Hodgkin's disease observed between January 1983 and December 1990, received radiotherapy only. The complete response rate was 98% (97/99). Twenty-one patients (21%) relapsed, 17 of whom (81%) obtained a second complete remission. The projected 9-year overall survi...

journal_title：Leukemia & lymphoma

authors： Zinzani PL,Barbieri E,Gherlinzoni F,Frezza G,Mazza P,Pica A,Ammendolia I,Bendandi M,Neri S,Miniaci G

更新日期：1994-04-01 00:00:00

abstract：:The aim of this research was to determine the serum dipeptidyl peptidase IV (DPPIV) activity as well as the percentages of CD26 + lymphocytes and CD26 + overall white blood cells in patients with hematological malignancies: non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), leukemia, plasmacytoma and multiple myeloma,...

journal_title：Leukemia & lymphoma

authors： Matić IZ,Đorđević M,Đorđić M,Grozdanić N,Damjanović A,Kolundžija B,Vidović A,Bila J,Ristić S,Mihaljević B,Tomin D,Milanović N,Ristić D,Purić M,Gavrilović D,Cordero OJ,Juranić ZD

更新日期：2013-12-01 00:00:00

abstract：:A man in late middle age presented with fever, systemic symptoms, raised inflammatory markers and anaemia of chronic disease. Despite two months of investigation, the diagnosis of a haematological malignancy was made only at autopsy. ...

journal_title：Leukemia & lymphoma

authors： Gabriel IH,Chong N,Rice A,Negus R,Bain BJ

更新日期：2007-07-01 00:00:00

abstract：:To elucidate the pathogenesis of angioimmunoblastic lymphadenopathy-like T cell lymphoma (AILD-T) we investigated the T cell receptor V beta gene repertoires of four AILD-Ts and compared them with those of other histological types of lymphomas and three cases with reactive disorders. All lymphoma patients had rearrang...

journal_title：Leukemia & lymphoma

authors： Araki A,Taniguchi M,Mikata A

更新日期：1994-12-01 00:00:00

abstract：:Using the single-strand conformation polymorphism and heteroduplex analyses, the P53 and RB genes were analyzed in cell samples from twenty-eight patients with chronic myeloid leukemia (CML) both at diagnosis and at the onset of accelerated phase (AP) of the disease. No alterations of the P53 or RB genes were found in...

journal_title：Leukemia & lymphoma

authors： Beck Z,Kiss A,Tóth FD,Szabó J,Bácsi A,Balogh E,Borbély A,Telek B,Kovács E,Oláh E,Rak K

更新日期：2000-08-01 00:00:00